Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by Brokerages

Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has received a consensus rating of "Buy" from the eight brokerages that are covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $14.25.

INZY has been the subject of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of Inozyme Pharma in a research report on Thursday, April 10th. Wedbush reiterated an "outperform" rating and set a $7.00 target price (down previously from $12.00) on shares of Inozyme Pharma in a research report on Monday, March 10th. Needham & Company LLC dropped their target price on shares of Inozyme Pharma from $15.00 to $12.00 and set a "buy" rating for the company in a research report on Wednesday. Piper Sandler lowered their price objective on shares of Inozyme Pharma from $30.00 to $23.00 and set an "overweight" rating for the company in a research report on Tuesday, March 11th. Finally, Raymond James lowered their price objective on shares of Inozyme Pharma from $24.00 to $12.00 and set an "outperform" rating for the company in a research report on Wednesday, March 12th.

Institutional Investors Weigh In On Inozyme Pharma

Several institutional investors have recently modified their holdings of INZY. Affinity Asset Advisors LLC grew its position in shares of Inozyme Pharma by 40.7% during the 4th quarter. Affinity Asset Advisors LLC now owns 3,972,318 shares of the company's stock worth $11,003,000 after buying an additional 1,150,000 shares during the period. Sanofi acquired a new stake in shares of Inozyme Pharma during the 4th quarter worth approximately $1,228,000. Renaissance Technologies LLC grew its position in shares of Inozyme Pharma by 155.7% during the 4th quarter. Renaissance Technologies LLC now owns 421,399 shares of the company's stock worth $1,167,000 after buying an additional 256,599 shares during the period. Walleye Capital LLC acquired a new stake in shares of Inozyme Pharma during the 4th quarter worth approximately $658,000. Finally, Pale Fire Capital SE grew its position in shares of Inozyme Pharma by 101.7% during the 1st quarter. Pale Fire Capital SE now owns 440,807 shares of the company's stock worth $401,000 after buying an additional 222,270 shares during the period. Institutional investors and hedge funds own 88.30% of the company's stock.

Inozyme Pharma Price Performance

NASDAQ:INZY opened at $1.35 on Thursday. The company has a market capitalization of $87.16 million, a price-to-earnings ratio of -0.87 and a beta of 1.35. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The company has a 50-day moving average of $1.03 and a 200-day moving average of $1.92. Inozyme Pharma has a 52 week low of $0.72 and a 52 week high of $6.24.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.01). As a group, equities research analysts anticipate that Inozyme Pharma will post -1.59 earnings per share for the current fiscal year.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.